LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Center
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CDMO
      • CDMO Service
      • Core Value
      • Manufacturing
      • Global CDMO
      • CDMO Inquiries
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
    • LUCATREE Advanced Regenerative Medicine
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • CDMO Inquiries
    • IR Inquiries

Mechanism of treatment for cartilage regeneration using stem cells, the first in the world

2013/06/23
STEM CELL THERAPEUTIC

MEDIPOST, will do research into the promotion of cartilage cell division by a specific protein…published in Stem Cell

A Korean group of researchers have found that a specific protein can promote the division of cartilage.

MEDIPOST has stated that the study on ‘The Mechanism of cartilage regeneration treatment using stem cells’ was published in one of the top journals in stem cell research, Stem Cell, on July 23.

MEDIPOST has produced results that the administration of mesenchymal stem cells extracted from the cord into the damaged knee joints of animals led to precursor cartilage cell division by various proteins, including TSAP-2, and published these results.

This study is meaningful in the era of various stem cell researches into cartilage regeneration treatment, because it has tested the hypothesis that ‘stem cells do not directly become cartilage cells, but rather, secrete specific proteins to induce cartilage production’.

The utilization of these results can lead to adjustment of the level of secretion of effective proteins within the stem cell treatment agent, or develop the optimal administration route and method, which can improve the success rate of cartilage regeneration treatment.

Stem Cell, which is where this study was published in, is one of the oldest and well known journals, with a SCI factor and IF of 7.701.

The related person from MEDIPOST said that ‘the publication of this study is to scientifically prove the mechanism of action of ‘CARTISTEM’ and have it recognized by the world’, and added, ‘this will hopefully lead to vitalization of cartilage-related research and the development of second generation CARTISTEM’.

VIEW LIST

Related News

knee img
MEDIPOST Inc. Treats First U.S. Participant in Phase III Tri…
2026/07/07
cdmo img33
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Stu…
2026/06/04

Latest News

knee img
MEDIPOST Inc. Treats First U.S. Participant in Phase III Tri…
2026/07/07
cdmo img33
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Stu…
2026/06/04
news
MEDIPOST’s CARTISTEM® Meets All Primary and Secondary…
2026/05/13
medipost img 2
MEDIPOST, INC. ANNOUNCES $140 MILLION IN FUNDING TO ACCELERA…
2026/01/09
knee img
MEDIPOST Inc. Treats First U.S. Participant in Phase III Tri…
2026/07/07
cdmo img33
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Stu…
2026/06/04
news
MEDIPOST’s CARTISTEM® Meets All Primary and Secondary…
2026/05/13
medipost img 2
MEDIPOST, INC. ANNOUNCES $140 MILLION IN FUNDING TO ACCELERA…
2026/01/09

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

Latest News

MEDIPOST Inc. Treats First U.S. Particip…2026.07.07
MEDIPOST Secures FDA Agreement on Single…2026.06.04
MEDIPOST’s CARTISTEM® Meets All Pr…2026.05.13
MEDIPOST, INC. ANNOUNCES $140 MILLION IN…2026.01.09
MEDIPOST Announces the Exclusive Commerc…2025.12.19

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST